A compressive review about Taxol® : history and future challenges

Gallego Jara, Julia; Lozano Terol, Gema; Cánovas Díaz, Manuel; Diego Puente, Teresa de; Sola Martínez, Rosa Alba

Publication:
A compressive review about Taxol® : history and future challenges

dc.contributor.author	Gallego Jara, Julia
dc.contributor.author	Lozano Terol, Gema
dc.contributor.author	Cánovas Díaz, Manuel
dc.contributor.author	Diego Puente, Teresa de
dc.contributor.author	Gallego Jara, Julia
dc.contributor.author	Sola Martínez, Rosa Alba
dc.contributor.department	Bioquímica y Biología Molecular B e Inmunología
dc.date.accessioned	2023-12-11T23:11:26Z
dc.date.available	2023-12-11T23:11:26Z
dc.date.issued	2020-12-17
dc.description	©2020. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the Published, version of a Published Work that appeared in final form in Molecules. To access the final edited and published work see https://doi.org/10.3390/molecules25245986
dc.description.abstract	Taxol®, which is also known as paclitaxel, is a chemotherapeutic agent widely used to treat different cancers. Since the discovery of its antitumoral activity, Taxol® has been used to treat over one million patients, making it one of the most widely employed antitumoral drugs. Taxol® was the first microtubule targeting agent described in the literature, with its main mechanism of action consisting of the disruption of microtubule dynamics, thus inducing mitotic arrest and cell death. However, secondary mechanisms for achieving apoptosis have also been demonstrated. Despite its wide use, Taxol® has certain disadvantages. The main challenges facing Taxol® are the need to find an environmentally sustainable production method based on the use of microorganisms, increase its bioavailability without exerting adverse effects on the health of patients and minimize the resistance presented by a high percentage of cells treated with paclitaxel. This review details, in a succinct manner, the main aspects of this important drug, from its discovery to the present day. We highlight the main challenges that must be faced in the coming years, in order to increase the effectiveness of Taxol® as an anticancer agent.
dc.format	application/pdf	es_ES
dc.format.extent	24
dc.identifier.citation	Molecules (2020) 25, 5986
dc.identifier.doi	https://doi.org/10.3390/molecules25245986
dc.identifier.issn	1420-3049
dc.identifier.uri	http://hdl.handle.net/10201/136505
dc.language	eng	es_ES
dc.publisher	MDPI
dc.relation	Sin financiación externa a la Universidad
dc.relation.isreferencedby	ED_IDENTRADA=1250
dc.rights	info:eu-repo/semantics/openAccess
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject	Drug
dc.subject	Cancer
dc.subject	Cell death
dc.subject	Biotechnology
dc.subject	Antitumor agent
dc.title	A compressive review about Taxol® : history and future challenges	es_ES
dc.type	info:eu-repo/semantics/article	es_ES
dspace.entity.type	Publication	es
relation.isAuthorOfPublication	57bf3537-1124-49ab-8774-bd0c3bdf1c28
relation.isAuthorOfPublication	b8be181a-7224-475a-8427-543751ef593c
relation.isAuthorOfPublication	0212fc0f-e15c-4b27-9a2d-116768a47044
relation.isAuthorOfPublication	e8f94992-2fb5-4cef-8d69-f99f31938719
relation.isAuthorOfPublication.latestForDiscovery	57bf3537-1124-49ab-8774-bd0c3bdf1c28